TSC2 and prostate carcinoma: Remarkably, up to 3%, 4%, and 7% of patients with prostate cancer also display TBC1D7, TSC1, and TSC2 high-level amplification respectively (Tables S1–S3), yet the functional consequence is currently unclear.